• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Robyn J. Barst, Lewis J. Rubin, +17 authors James W. Crow
  • Medicine
  • The New England journal of medicine
  • 1996 (First Publication: 1 February 1996)
  • BACKGROUND Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival. METHODS We conducted a 12-weekExpand
  • Gérald Simonneau, Robyn J. Barst, +9 authors Lewis J. Rubin
  • Medicine
  • American journal of respiratory and critical care…
  • 2002 (First Publication: 15 March 2002)
  • Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be effective. However, this treatment requires a permanent central venousExpand
  • Alan L. Hinderliter, Park W. Willis, +13 authors James W. Crow
  • Medicine
  • The American journal of cardiology
  • 1999 (First Publication: 1 August 1999)
  • Pericardial effusion was noted in 43 of 79 patients (54%) with severe primary pulmonary hypertension. Larger effusion was associated with hemodynamic and echocardiographic evidence of right heartExpand
  • Alan L. Hinderliter, Park W. Willis, +13 authors James W. Crow
  • Medicine
  • The American journal of cardiology
  • 2003 (First Publication: 1 April 2003)
  • W previously described a high prevalence of functional tricuspid regurgitation (TR) in patients with severely symptomatic primary pulmonary hypertension (PPH).1 We report the relations of TR to rightExpand
  • Richard D. Swartz, Walter Flamenbaum, A Dubrow, Julian C. Hall, James W. Crow, Allen Cato
  • Medicine
  • Journal of clinical pharmacology
  • 1988 (First Publication: 1 September 1988)
  • The frequency of hemodialysis-associated hemorrhage was studied prospectively in two successive, parallel, heparin-controlled studies using epoprostenol (PGI2; average dose, 4.1 ng/kg.min) as theExpand
  • Randall M. Zusman, Robert Howard Rubin, Allen E. Cato, David M. Cocchetto, James W. Crow, Nina E. Tolkoff-Rubin
  • Medicine
  • The New England journal of medicine
  • 1981 (First Publication: 16 April 1981)
  • Anticoagulation during hemodialysis is necessary to prevent clotting of the blood on contact with the dialysis membrane. Heparin is the usual anticoagulant used, but systemic anticoagulation mayExpand